Magali Gary-Bobo studied at the Montpellier Faculty of Science. She completed a CIFRE thesis between the Sanofi laboratories and the IGF under the supervision of Mohammed Bensaïd and Joël Bockaert, and obtained her doctorate from the University of Montpellier in 2006. Her thesis focused on the regulation of adiponectin and its role on metabolic syndrome. She then did a postdoctoral internship at INSERM in Marcel Garcia's group on lysosomal diseases, then at IBMM on the development of photoactivatable nanoparticles for cancer therapy. She was recruited to IBMM as a CNRS Chargée de Recherche in 2012, and in the same year was one of the founders of the NanoMedSyn spin-off. Today, with Alain Morère, she co-leads the F14 team: Glyco and NanoVectors for Therapeutic Targeting.